{
  "id": "NCT06044857",
  "type": "trial",
  "status": "Recruiting",
  "studyCompletion": "2026-11",
  "name": "PSMA PET Response Guided SabR in High Risk Pca",
  "description": "Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose.",
  "phase": "1",
  "link": "https://clinicaltrials.gov/study/NCT06044857",
  "patientsFilter":{
    "filter": {
      "must": [
        {
          "attributes.gender": {
            "eq": "male"
          }
        }
      ]
    }
  },
  "variables": [
    {
      "id": "age",
      "definition": {
        "ai": {
          "criteria": "Age ≥ 18 years."
        }
      },
      "display": "Patient's date of birth"
    },
    {
      "id": "gender",
      "definition": {
        "ai": {
          "criteria": "gender is male."
        }
      },
      "display": "Patient's gender"
    },
    {
      "id": "histologically",
      "definition": {
        "ai": {
          "criteria": "Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NCCN) criteria as determined by >=cT3a stage (AJCC 8th edition) OR PSA>20ng/mL OR ISUP Grade Group 4-5 (Gleason Grade 8-10)."
        }
      },
      "display": "Patient's histologic type"
    },
    {
      "id": "comorbidity",
      "definition": {
        "ai": {
          "criteria": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements."
        }
      },
      "display": "Patient's comorbidity"
    },
    {
      "id": "imaging_pet_ct_dates",
      "definition": {
        "ai": {
          "criteria": "Staging 68Ga PMSA-11 PET -CT performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes <=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment."
        }
      },
      "display": "Patient imging date"
    },
    {
      "id": "imaging_pet_mri_dates",
      "definition": {
        "ai": {
          "criteria": "Staging 68Ga PMSA-11 PET -MRI performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes <=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment."
        }
      },
      "display": "Patient imging date"
    },
    {
      "id": "SabR_ADT",
      "definition": {
        "ai": {
          "criteria": "Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivation therapy (ADT) with baseline AUA IPSS <=18 and prostate size <=100cc"
        }
      },
      "display": "Patient's planned SabR"
    },
    {
      "id": "PSMA_pet_ct",
      "definition": {
        "ai": {
          "criteria": "Staging 68Ga PSMA-11 PET -CT demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost."
        }
      },
      "display": "PSMA"
    },
    {
      "id": "PSMA_pet_mri",
      "definition": {
        "ai": {
          "criteria": "Staging 68Ga PSMA-11 PET -MRI demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost."
        }
      },
      "display": "PSMA"
    },
    {
      "id": "pelvic_radiotherapy",
      "definition": {
        "ai": {
          "criteria": "Prior pelvic radiotherapy other than cutaneous/superficial treatments."
        }
      },
      "display": "pelvic_radiotherapy"
    },
    {
      "id": "agreement",
      "definition": {
        "ai": {
          "criteria": "All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SabR and for a period of time of 6 months thereafter as per standard guidelines. Should a man's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately."
        }
      },
      "display": "Patient's agreement"
    },
    {
      "id": "qualifications",
      "definition": {
        "ai": {
          "criteria": "Ability to understand and the willingness to sign a written informed consent."
        }
      },
      "display": "Patient's qualifications"
    },
    {
      "id": "ADT",
      "definition": {
        "ai": {
          "criteria": "Prior curative intent local therapy (e.g. prostatectomy, radiotherapy, focal ablative therapy) for prostate cancer is not allowed, with following exceptions regarding androgen deprivation therapy (ADT)/anti-androgen therapy (AAT): Prior androgen deprivation therapy (ADT) allowed if <3 month total duration and stopped >=3 months prior to registration with demonstration of non-castrate testosterone recovery (>50ng/dL) and meeting all other inclusion criteria. Ongoing androgen deprivation therapy (ADT) is allowed if <=60 days total duration AND meeting following criteria:If GnRH agonist used (e.g. leuprolide), bicalutamide must have been used for at least 30 days +/-14 days from start of GnRH agonist."
        }
      },
      "display": "ADT"
    },
    {
      "id": "investigational_agents",
      "definition": {
        "ai": {
          "criteria": "Subjects may not be receiving any other investigational agents for the treatment of the cancer under study."
        }
      },
      "display": "may not be receiving any other investigational agents"
    },
    {
      "id": "allergy",
      "definition": {
        "ai": {
          "criteria": "History of allergic reactions to PMSA-11 68Ga imaging agent."
        }
      },
      "display": "allergy"
    }
  ],
  "criteria": [
    {
      "id": "criteria_male",
      "type": "inclusion",
      "title": "Gender is male",
      "allowMissingVariables": [
        "gender"
      ],
      "dependency": [
        "gender"
      ],
      "expression": "gender",
      "subCriteria": [
        {
          "id": "gender",
          "title": "Gender is male",
          "description": "Gender is male",
          "expression": "variables.gender.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.gender.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_age",
      "type": "inclusion",
      "title": "Age ≥ 18 years.",
      "allowMissingVariables": [
        "age"
      ],
      "dependency": [
        "age"
      ],
      "expression": "age",
      "subCriteria": [
        {
          "id": "age",
          "title": "Age ≥ 18 years.",
          "description": "",
          "expression": "variables.age.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.age.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_histologic_type",
      "type": "inclusion",
      "title": "Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NCCN) criteria as determined by >=cT3a stage (AJCC 8th edition) OR PSA>20ng/mL OR ISUP Grade Group 4-5 (Gleason Grade 8-10).",
      "allowMissingVariables": [
        "histologically"
      ],
      "dependency": [
        "histologically"
      ],
      "expression": "histologically",
      "subCriteria": [
        {
          "id": "histologically",
          "title": "Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NCCN) criteria as determined by >=cT3a stage (AJCC 8th edition) OR PSA>20ng/mL OR ISUP Grade Group 4-5 (Gleason Grade 8-10).",
          "description": "Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NCCN) criteria as determined by >=cT3a stage (AJCC 8th edition) OR PSA>20ng/mL OR ISUP Grade Group 4-5 (Gleason Grade 8-10).",
          "expression": "variables.histologically.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.histologically.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_SabR_ADT",
      "type": "inclusion",
      "title": "Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivation therapy (ADT) with baseline AUA IPSS <=18 and prostate size <=100cc",
      "allowMissingVariables": [
        "SabR_ADT"
      ],
      "dependency": [
        "SabR_ADT"
      ],
      "expression": "SabR_ADT",
      "subCriteria": [
        {
          "id": "SabR_ADT",
          "title": "Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivation therapy (ADT) with baseline AUA IPSS <=18 and prostate size <=100cc",
          "description": "Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivation therapy (ADT) with baseline AUA IPSS <=18 and prostate size <=100cc",
          "expression": "variables.SabR_ADT.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.SabR_ADT.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_imaging_dates",
      "type": "inclusion",
      "title": "Staging 68Ga PMSA-11 PET -CT or -MRI performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes <=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment.",
      "dependency": [
        "imaging_pet_ct_dates",
        "imaging_pet_mri_dates"
      ],
      "expression": "imaging_pet_ct_dates || imaging_pet_mri_dates",
      "subCriteria": [
        {
          "id": "imaging_pet_ct_dates",
          "title": "Staging 68Ga PMSA-11 PET-CT date",
          "description": "Staging 68Ga PMSA-11 PET -CT performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes <=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment.",
          "expression": "variables.imaging_pet_ct_dates.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.imaging_pet_ct_dates.value.reasoning.join(' ', @)"
          }
        },
        {
          "id": "imaging_pet_mri_dates",
          "title": "Staging 68Ga PMSA-11 PET-MRI date",
          "description": "Staging 68Ga PMSA-11 PET -MRI performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes <=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment.",
          "expression": "variables.imaging_pet_mri_dates.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.imaging_pet_mri_dates.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_PSMA",
      "type": "inclusion",
      "title": "Staging 68Ga PSMA-11 PET -CT or -MRI demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost",
      "dependency": [
        "PSMA_pet_ct",
        "PSMA_pet_mri"
      ],
      "expression": "PSMA_pet_ct || PSMA_pet_mri",
      "subCriteria": [
        {
          "id": "PSMA_pet_ct",
          "title": "Staging 68Ga PSMA-11 PET-CT",
          "description": "Staging 68Ga PSMA-11 PET -CT demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost",
          "expression": "variables.PSMA_pet_ct.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.PSMA_pet_ct.value.reasoning.join(' ', @)"
          }
        },
        {
          "id": "PSMA_pet_mri",
          "title": "Staging 68Ga PSMA-11 PET-MRI",
          "description": "Staging 68Ga PSMA-11 PET -MRI demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost",
          "expression": "variables.PSMA_pet_mri.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.PSMA_pet_mri.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_agreement",
      "type": "inclusion",
      "title": "All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SabR and for a period of time of 6 months thereafter as per standard guidelines. Should a man's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",
      "allowMissingVariables": [
        "agreement"
      ],
      "dependency": [
        "agreement"
      ],
      "expression": "agreement",
      "subCriteria": [
        {
          "id": "agreement",
          "title": "All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SabR and for a period of time of 6 months thereafter as per standard guidelines. Should a man's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",
          "description": "All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SabR and for a period of time of 6 months thereafter as per standard guidelines. Should a man's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",
          "expression": "variables.agreement.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.agreement.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_qualifications",
      "type": "inclusion",
      "title": "Ability to understand and the willingness to sign a written informed consent.",
      "dependency": [
        "qualifications"
      ],
      "expression": "qualifications",
      "subCriteria": [
        {
          "id": "qualifications",
          "title": "Ability to understand and the willingness to sign a written informed consent.",
          "description": "Ability to understand and the willingness to sign a written informed consent.",
          "expression": "variables.qualifications.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.qualifications.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_ADT",
      "type": "exclusion",
      "title": "Prior curative intent local therapy (e.g. prostatectomy, radiotherapy, focal ablative therapy) for prostate cancer is not allowed, with following exceptions regarding androgen deprivation therapy (ADT)/anti-androgen therapy (AAT): Prior androgen deprivation therapy (ADT) allowed if <3 month total duration and stopped >=3 months prior to registration with demonstration of non-castrate testosterone recovery (>50ng/dL) and meeting all other inclusion criteria. Ongoing androgen deprivation therapy (ADT) is allowed if <=60 days total duration AND meeting following criteria:If GnRH agonist used (e.g. leuprolide), bicalutamide must have been used for at least 30 days +/-14 days from start of GnRH agonist.",
      "allowMissingVariables": [
        "ADT"
      ],
      "dependency": [
        "ADT"
      ],
      "expression": "ADT",
      "subCriteria": [
        {
          "id": "ADT",
          "title": "Prior curative intent local therapy (e.g. prostatectomy, radiotherapy, focal ablative therapy) for prostate cancer is not allowed, with following exceptions regarding androgen deprivation therapy (ADT)/anti-androgen therapy (AAT): Prior androgen deprivation therapy (ADT) allowed if <3 month total duration and stopped >=3 months prior to registration with demonstration of non-castrate testosterone recovery (>50ng/dL) and meeting all other inclusion criteria. Ongoing androgen deprivation therapy (ADT) is allowed if <=60 days total duration AND meeting following criteria:If GnRH agonist used (e.g. leuprolide), bicalutamide must have been used for at least 30 days +/-14 days from start of GnRH agonist.",
          "description": "",
          "expression": "variables.ADT.value.response == `INELIGIBLE`",
          "explainability": {
            "displayValue": "variables.ADT.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_investigational_agents",
      "type": "exclusion",
      "title": "Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.",
      "dependency": [
        "investigational_agents"
      ],
      "expression": "investigational_agents",
      "subCriteria": [
        {
          "id": "investigational_agents",
          "title": "Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.",
          "description": "",
          "expression": "variables.investigational_agents.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.investigational_agents.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_allergy",
      "type": "exclusion",
      "title": "History of allergic reactions to PMSA-11 68Ga imaging agent",
      "allowMissingVariables": [
        "allergy"
      ],
      "dependency": [
        "allergy"
      ],
      "expression": "allergy",
      "subCriteria": [
        {
          "id": "allergy",
          "title": "History of allergic reactions to PMSA-11 68Ga imaging agent",
          "description": "",
          "expression": "variables.allergy.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.allergy.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_comorbidity",
      "type": "exclusion",
      "title": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.",
      "expression": "comorbidity",
      "dependency": [
        "comorbidity"
      ],
      "subCriteria": [
        {
          "id": "comorbidity",
          "title": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.",
          "description": "",
          "expression": "variables.comorbidity.value.response == `ELIGIBLE`",
          "explainability": {
            "displayValue": "variables.comorbidity.value.reasoning.join(' ', @)"
          }
        }
      ]
    },
    {
      "id": "criteria_pelvic_radiotherapy",
      "type": "exclusion",
      "title": "Prior pelvic radiotherapy other than cutaneous/superficial treatments.",
      "allowMissingVariables": [
        "pelvic_radiotherapy"
      ],
      "dependency": [
        "pelvic_radiotherapy"
      ],
      "expression": "pelvic_radiotherapy",
      "subCriteria": [
        {
          "id": "pelvic_radiotherapy",
          "title": "Prior pelvic radiotherapy other than cutaneous/superficial treatments.",
          "description": "",
          "expression": "variables.pelvic_radiotherapy.value.response == `INELIGIBLE`",
          "explainability": {
            "displayValue": "variables.pelvic_radiotherapy.value.reasoning.join(' ', @)"
          }
        }
      ]
    }
  ]
}